复宏汉霖(02696.HK)：汉斯状联合化疗用于胃癌新辅助/辅助治疗获国家药监局正式纳入突破性治疗药物程序

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), announced that its drug Hansizhuang® (sulunatuzumab injection) has been officially included in the breakthrough therapy designation process by the National Medical Products Administration (NMPA) for the neoadjuvant/adjuvant treatment of gastric cancer [1] Group 1 - Junshi Biosciences' drug Hansizhuang® has received recognition from the NMPA, indicating a significant step in its development for gastric cancer treatment [1] - The inclusion in the breakthrough therapy designation process suggests potential expedited review and approval, which could enhance the drug's market entry timeline [1]